Everything we've seen

1. ?Sep 14, 3:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

2. !Sep 14, 3:20 PMsignalseverity 0.16

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

3. ?Sep 14, 3:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

4. !Sep 14, 3:20 PMsignalseverity 0.16

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

5. ?Sep 14, 2:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

6. !Sep 14, 2:20 PMsignalseverity 0.17

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

7. ?Sep 14, 2:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

8. !Sep 14, 2:20 PMsignalseverity 0.17

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

9. ?Sep 14, 1:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

10. !Sep 14, 1:20 PMsignalseverity 0.17

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

11. ?Sep 14, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

12. !Sep 14, 1:20 PMsignalseverity 0.17

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

13. ?Sep 14, 12:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

14. !Sep 14, 12:20 PMsignalseverity 0.16

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

15. ?Sep 14, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

16. !Sep 14, 12:20 PMsignalseverity 0.16

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

17. ?Sep 14, 11:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

18. !Sep 14, 11:21 AMsignalseverity 0.16

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

19. ?Sep 14, 11:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

20. !Sep 14, 11:21 AMsignalseverity 0.16

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

21. ?Sep 14, 10:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

22. !Sep 14, 10:21 AMsignalseverity 0.16

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

23. ?Sep 14, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

24. !Sep 14, 10:21 AMsignalseverity 0.16

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

25. ?Sep 14, 7:01 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

26. !Sep 14, 7:01 AMsignalseverity 0.16

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

27. ?Sep 14, 7:00 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

28. !Sep 14, 7:00 AMsignalseverity 0.16

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

29. ?Sep 11, 6:04 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    BAX (Baxter International) is down 16.1% from its 30-day high with no news headlines in the window to explain the move, suggesting this may be a technically driven or macro-driven selloff rather than company-specific deterioration. However, the three recent 8-K filings lack financial metrics, leaving the fundamental picture opaque, and the macro context shows 5-year forward inflation expectations running 1.8σ above trend — a headwind for rate-sensitive, capital-intensive healthcare companies like Baxter that carry significant debt from prior restructuring. The combination of elevated inflation expectations, thin fundamental evidence, and Baxter's historically challenged balance sheet tempers confidence in a near-term mean reversion.

30. !Sep 11, 6:04 PMsignalseverity 0.16

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    BAX (Baxter International) is down 16.1% from its 30-day high with no news headlines in the window to explain the move, suggesting this may be a technically driven or macro-driven selloff rather than company-specific deterioration. However, the three recent 8-K filings lack financial metrics, leaving the fundamental picture opaque, and the macro context shows 5-year forward inflation expectations running 1.8σ above trend — a headwind for rate-sensitive, capital-intensive healthcare companies like Baxter that carry significant debt from prior restructuring. The combination of elevated inflation expectations, thin fundamental evidence, and Baxter's historically challenged balance sheet tempers confidence in a near-term mean reversion.

31. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

32. !Sep 11, 4:20 PMsignalseverity 0.16

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

33. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

34. !Sep 11, 4:20 PMsignalseverity 0.16

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

35. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

36. !Sep 11, 3:20 PMsignalseverity 0.16

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

37. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

38. !Sep 11, 3:20 PMsignalseverity 0.16

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

39. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

40. !Sep 11, 2:21 PMsignalseverity 0.16

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

41. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

42. !Sep 11, 2:21 PMsignalseverity 0.16

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

43. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

44. !Sep 11, 1:20 PMsignalseverity 0.16

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

45. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

46. !Sep 11, 1:20 PMsignalseverity 0.16

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

47. ?Sep 11, 12:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

48. !Sep 11, 12:21 PMsignalseverity 0.16

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

49. ?Sep 11, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

50. !Sep 11, 12:20 PMsignalseverity 0.16

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

51. ▣Sep 10, 8:00 PMjournalstop

    Agent 20 — SIR Price/Volume closed long 66 @ $23.73 (-$200.64)

    intraday stop sweep

52. ?Sep 10, 4:26 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

53. !Sep 10, 4:26 PMsignalseverity 0.19

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

54. ?Sep 10, 4:26 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

55. !Sep 10, 4:26 PMsignalseverity 0.19

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

56. ?Sep 10, 9:51 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is down 1.74% intraday with no attributable headline catalyst. The move is meaningful but sits just below the 2% threshold that would suggest strong institutional conviction. With 355 minutes remaining (nearly a full session still ahead), there is ample time for continuation but also for mean reversion. The macro backdrop shows elevated 5Y5Y inflation forwards (2.33, +1.6σ above trend), which pressures rate-sensitive and defensive healthcare names like BAX modestly — consistent with the down move but not a strong amplifier. No news means we cannot confirm a fundamental catalyst driving sellers; the move could be technical or sector-rotation-driven. With no reversal signals evident and time remaining sufficient for another leg, the base case is mild continuation of the downside bias, but conviction is low. Assigning the minimum threshold for a down position given the absence of countervailing evidence and the system's asymmetric risk structure.

57. !Sep 10, 9:51 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    BAX is down 1.74% intraday with no attributable headline catalyst. The move is meaningful but sits just below the 2% threshold that would suggest strong institutional conviction. With 355 minutes remaining (nearly a full session still ahead), there is ample time for continuation but also for mean reversion. The macro backdrop shows elevated 5Y5Y inflation forwards (2.33, +1.6σ above trend), which pressures rate-sensitive and defensive healthcare names like BAX modestly — consistent with the down move but not a strong amplifier. No news means we cannot confirm a fundamental catalyst driving sellers; the move could be technical or sector-rotation-driven. With no reversal signals evident and time remaining sufficient for another leg, the base case is mild continuation of the downside bias, but conviction is low. Assigning the minimum threshold for a down position given the absence of countervailing evidence and the system's asymmetric risk structure.

58. ?Sep 9, 4:25 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

59. !Sep 9, 4:25 PMsignalseverity 0.19

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

60. ?Sep 9, 4:25 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

61. !Sep 9, 4:25 PMsignalseverity 0.19

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

62. ❖Sep 9, 11:37 AMnewsvia finnhub

    Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Baxter International Inc. (BAX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 12:45 PM EDTCompany ParticipantsAndrew Hider - CEO,...

63. ▣Sep 8, 8:00 PMjournalstop

    Agent 5 — Dip Buyer (Evolving) closed long 1 @ $24.41 (-$2.20)

    intraday stop sweep

64. ▣Sep 8, 8:00 PMjournalstop

    Agent 5 — Dip Buyer (Evolving) closed long 1 @ $24.41 (-$2.20)

    Stop hit: close $24.41 ≤ stop $24.48

65. ▣Sep 8, 8:00 PMjournalstop

    Agent 4 — Dip Buyer (Frozen) closed long 104 @ $24.49 (-$237.64)

    intraday stop sweep

66. ?Sep 8, 4:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

67. ?Sep 8, 3:40 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    With only 5 minutes remaining until the forced close, there is virtually no time for meaningful continuation. Even a strong directional setup cannot be acted upon effectively in this window. The -3.70% move is significant and does represent real flow, but at this point in the session the dominant dynamic shifts to position squaring and EOD flattening rather than momentum continuation. No news catalyst is available to explain the move, and the elevated 5Y5Y inflation forward (2.33, 1.7σ above trend) creates a mildly adverse macro backdrop for rate-sensitive names like BAX, but this is not a strong directional driver here. The lack of time remaining is the decisive factor — probability is set below 0.5 to avoid a 5-minute hold with no room to run to the +3% target before forced flatten.

68. ?Sep 8, 1:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

69. ?Sep 8, 11:25 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX raised its 2026 outlook following strong Q2 growth, suggesting the fundamental story remains intact and the 17.3% drop appears to be an overreaction rather than a reflection of lasting impairment. However, margin pressure noted in the headline introduces some concern, and the options flow is essentially neutral (P/C ratio of 1.03, both volumes below average z-scores) — no unusual call buying to confirm informed accumulation. There are no insider purchases to anchor conviction, and the sector (Health Care) is outperforming the market, meaning BAX's idiosyncratic drop warrants scrutiny of an unidentified company-specific headwind. With earnings 50 days out and the macro environment featuring elevated 10Y yields (4.77%) as a structural headwind for rate-sensitive health care names, the setup is mixed but not clearly negative.

70. ?Sep 8, 10:41 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is down 2.79% intraday, which is meaningful flow. However, the dominant counterweight is last evening's headline: BAX raised its 2026 outlook on strong Q2 growth. This is a bullish fundamental catalyst that likely explains why the stock has not broken down further — there is a credible bid from investors viewing this pullback as an opportunity after positive guidance. The intraday decline may reflect early profit-taking or rate-sensitivity (T5YIFR running 1.7σ above trend pressures rate-sensitive names broadly), but the raised outlook gives buyers a fundamental anchor to lean on into the close. With 304 minutes remaining there is ample time for a reversal toward fair value. The combination of bullish overnight news + elevated inflation expectations (which could cap further downside in a defensive healthcare name like BAX that benefits from pricing power) + meaningful time remaining creates a setup where the down move is more likely to fade than continue. Probability of continuation below 0.5.

71. ❖Sep 8, 8:05 AMnewsvia finnhub

    Reported Earlier, Medline Prices Secondary Offering Of 75M Class A Shares At $41.00/Share By Blackstone, Carlyle, Hellman & Friedman And ADIA Affiliates

72. ❖Sep 7, 3:38 PMnewsvia finnhub

    BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure

    Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.

73. ❖Sep 7, 6:57 AMnewsvia finnhub

    Drug Reconstitution Systems Market Trends, Shares and Growth Opportunities Worldwide 2026-2035 Featuring Profiles of Baxter, ICU Medical, B. Braun, Vetter Pharma, Nipro, SCHOTT-KAISHA

    Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Drug Reconstitution Systems Market - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global drug reconstitution systems market is projected to increase from approximately USD 5.9 billion in 2026 to USD 10.8 billion by 2035, representing a compound annual growth rate (CAGR) of about 7.0% during the forecast period. Market expansion is being supported by the growing pipeline of biologics, biosimilars, vaccines,

74. ?Sep 4, 4:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 12.6% from its 30-day high with no news headlines or SEC filings providing fundamental context for the drop, suggesting it may be macro- or sector-driven rather than company-specific deterioration. However, the options flow shows highly unusual put volume (z=3.41) on the most recent trading day with a near-parity P/C ratio of 0.92, signaling elevated hedging or directional bearishness — a meaningful risk discount. Health care sector context is mixed (rank 4/11, slightly underperforming SPY on 30d), and earnings are 65 days out, making that a non-factor. With no insider buying to confirm the dip, no catalyst identified, and the macro backdrop of elevated 10Y yields (4.65%) and rising inflation expectations (T5YIFR at 1.8σ above trend), the setup lacks the asymmetric large-rebound characteristics required for a high-conviction buy.

75. ?Sep 4, 2:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 12.6% from its 30-day high with no news headlines or SEC filings providing fundamental context for the drop, suggesting it may be macro- or sector-driven rather than company-specific deterioration. However, the options flow shows highly unusual put volume (z=3.41) on the most recent trading day with a near-parity P/C ratio of 0.92, signaling elevated hedging or directional bearishness — a meaningful risk discount. Health care sector context is mixed (rank 4/11, slightly underperforming SPY on 30d), and earnings are 65 days out, making that a non-factor. With no insider buying to confirm the dip, no catalyst identified, and the macro backdrop of elevated 10Y yields (4.65%) and rising inflation expectations (T5YIFR at 1.8σ above trend), the setup lacks the asymmetric large-rebound characteristics required for a high-conviction buy.

76. ?Sep 4, 1:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 12.6% from its 30-day high with no news headlines or SEC filings providing fundamental context for the drop, suggesting it may be macro- or sector-driven rather than company-specific deterioration. However, the options flow shows highly unusual put volume (z=3.41) on the most recent trading day with a near-parity P/C ratio of 0.92, signaling elevated hedging or directional bearishness — a meaningful risk discount. Health care sector context is mixed (rank 4/11, slightly underperforming SPY on 30d), and earnings are 65 days out, making that a non-factor. With no insider buying to confirm the dip, no catalyst identified, and the macro backdrop of elevated 10Y yields (4.65%) and rising inflation expectations (T5YIFR at 1.8σ above trend), the setup lacks the asymmetric large-rebound characteristics required for a high-conviction buy.

77. ?Sep 4, 12:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 12.6% from its 30-day high with no news headlines or SEC filings providing fundamental context for the drop, suggesting it may be macro- or sector-driven rather than company-specific deterioration. However, the options flow shows highly unusual put volume (z=3.41) on the most recent trading day with a near-parity P/C ratio of 0.92, signaling elevated hedging or directional bearishness — a meaningful risk discount. Health care sector context is mixed (rank 4/11, slightly underperforming SPY on 30d), and earnings are 65 days out, making that a non-factor. With no insider buying to confirm the dip, no catalyst identified, and the macro backdrop of elevated 10Y yields (4.65%) and rising inflation expectations (T5YIFR at 1.8σ above trend), the setup lacks the asymmetric large-rebound characteristics required for a high-conviction buy.

78. ?Sep 3, 4:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 12.6% from its 30-day high with no news headlines or SEC filings providing fundamental context for the drop, suggesting it may be macro- or sector-driven rather than company-specific deterioration. However, the options flow shows highly unusual put volume (z=3.41) on the most recent trading day with a near-parity P/C ratio of 0.92, signaling elevated hedging or directional bearishness — a meaningful risk discount. Health care sector context is mixed (rank 4/11, slightly underperforming SPY on 30d), and earnings are 65 days out, making that a non-factor. With no insider buying to confirm the dip, no catalyst identified, and the macro backdrop of elevated 10Y yields (4.65%) and rising inflation expectations (T5YIFR at 1.8σ above trend), the setup lacks the asymmetric large-rebound characteristics required for a high-conviction buy.

79. ?Sep 3, 3:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 12.6% from its 30-day high with no news headlines or SEC filings providing fundamental context for the drop, suggesting it may be macro- or sector-driven rather than company-specific deterioration. However, the options flow shows highly unusual put volume (z=3.41) on the most recent trading day with a near-parity P/C ratio of 0.92, signaling elevated hedging or directional bearishness — a meaningful risk discount. Health care sector context is mixed (rank 4/11, slightly underperforming SPY on 30d), and earnings are 65 days out, making that a non-factor. With no insider buying to confirm the dip, no catalyst identified, and the macro backdrop of elevated 10Y yields (4.65%) and rising inflation expectations (T5YIFR at 1.8σ above trend), the setup lacks the asymmetric large-rebound characteristics required for a high-conviction buy.

80. ?Sep 3, 1:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 12.6% from its 30-day high with no news headlines or SEC filings providing fundamental context for the drop, suggesting it may be macro- or sector-driven rather than company-specific deterioration. However, the options flow shows highly unusual put volume (z=3.41) on the most recent trading day with a near-parity P/C ratio of 0.92, signaling elevated hedging or directional bearishness — a meaningful risk discount. Health care sector context is mixed (rank 4/11, slightly underperforming SPY on 30d), and earnings are 65 days out, making that a non-factor. With no insider buying to confirm the dip, no catalyst identified, and the macro backdrop of elevated 10Y yields (4.65%) and rising inflation expectations (T5YIFR at 1.8σ above trend), the setup lacks the asymmetric large-rebound characteristics required for a high-conviction buy.

81. ?Sep 3, 11:25 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 12.6% from its 30-day high with no news headlines or SEC filings providing fundamental context for the drop, suggesting it may be macro- or sector-driven rather than company-specific deterioration. However, the options flow shows highly unusual put volume (z=3.41) on the most recent trading day with a near-parity P/C ratio of 0.92, signaling elevated hedging or directional bearishness — a meaningful risk discount. Health care sector context is mixed (rank 4/11, slightly underperforming SPY on 30d), and earnings are 65 days out, making that a non-factor. With no insider buying to confirm the dip, no catalyst identified, and the macro backdrop of elevated 10Y yields (4.65%) and rising inflation expectations (T5YIFR at 1.8σ above trend), the setup lacks the asymmetric large-rebound characteristics required for a high-conviction buy.

82. ?Sep 3, 10:35 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is down ~1.95% intraday with 310 minutes (over 5 hours) remaining — essentially a full trading session still ahead, so there is ample time for continuation. The move is meaningful but sits just below the 2-5% 'high conviction' threshold. No headlines are available to explain the drop, which is neutral per instructions — absence of news does not disqualify. The macro context shows the 5-year forward inflation rate (T5YIFR) printing 1.7σ above its 24-month trend, suggesting elevated rate-sensitive pressure broadly. BAX, as a large-cap healthcare/medtech name, carries some rate sensitivity through its capital structure and valuation multiples, which could provide a mild macro tailwind to the downside move. There is no reversal signal evident (no fade back through highs described), and time remaining is substantial. However, the move is not dramatic enough to assign high conviction, and without volume data or a clear catalyst, this is a borderline read. Assigning a modest continuation probability just above 0.5, consistent with ordinary momentum and no strong reason to fade.

83. ❖Sep 2, 9:00 PMnewsvia finnhub

    3 Value Stocks We Keep Off Our Radar

    Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

84. ?Sep 2, 4:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 12.6% from its 30-day high with no news headlines or SEC filings providing fundamental context for the drop, suggesting it may be macro- or sector-driven rather than company-specific deterioration. However, the options flow shows highly unusual put volume (z=3.41) on the most recent trading day with a near-parity P/C ratio of 0.92, signaling elevated hedging or directional bearishness — a meaningful risk discount. Health care sector context is mixed (rank 4/11, slightly underperforming SPY on 30d), and earnings are 65 days out, making that a non-factor. With no insider buying to confirm the dip, no catalyst identified, and the macro backdrop of elevated 10Y yields (4.65%) and rising inflation expectations (T5YIFR at 1.8σ above trend), the setup lacks the asymmetric large-rebound characteristics required for a high-conviction buy.

85. ?Sep 2, 3:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 12.6% from its 30-day high with no news headlines or SEC filings providing fundamental context for the drop, suggesting it may be macro- or sector-driven rather than company-specific deterioration. However, the options flow shows highly unusual put volume (z=3.41) on the most recent trading day with a near-parity P/C ratio of 0.92, signaling elevated hedging or directional bearishness — a meaningful risk discount. Health care sector context is mixed (rank 4/11, slightly underperforming SPY on 30d), and earnings are 65 days out, making that a non-factor. With no insider buying to confirm the dip, no catalyst identified, and the macro backdrop of elevated 10Y yields (4.65%) and rising inflation expectations (T5YIFR at 1.8σ above trend), the setup lacks the asymmetric large-rebound characteristics required for a high-conviction buy.

86. ?Sep 2, 11:41 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is up 1.55% today with no attributable headline catalyst. The move is modest — below the 2% threshold where strong conviction is implied — but represents real flow nonetheless. Macro context shows the 5-year forward inflation rate (T5YIFR) printing 1.7σ above its 24-month trend, which creates a headwind for rate-sensitive sectors broadly. BAX as a medical device/healthcare name has some rate sensitivity (capital equipment, balance sheet leverage), which mildly argues against continuation in a rising-rate-expectations environment. However, with 245 minutes remaining until the forced close, there is ample time for the move to extend if underlying momentum is genuine. No reversal signals are evident from the data provided. The absence of news is not disqualifying per framework rules. Balancing the modest move magnitude (limits conviction on continuation), the mild macro headwind from elevated inflation expectations, and the substantial time remaining, this reads as a borderline but slightly positive continuation setup. Assigning 0.52 — lean long but with low conviction.

87. ?Sep 2, 7:06 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 12.6% from its 30-day high with no news headlines or SEC filings providing fundamental context for the drop, suggesting it may be macro- or sector-driven rather than company-specific deterioration. However, the options flow shows highly unusual put volume (z=3.41) on the most recent trading day with a near-parity P/C ratio of 0.92, signaling elevated hedging or directional bearishness — a meaningful risk discount. Health care sector context is mixed (rank 4/11, slightly underperforming SPY on 30d), and earnings are 65 days out, making that a non-factor. With no insider buying to confirm the dip, no catalyst identified, and the macro backdrop of elevated 10Y yields (4.65%) and rising inflation expectations (T5YIFR at 1.8σ above trend), the setup lacks the asymmetric large-rebound characteristics required for a high-conviction buy.

88. ?Sep 1, 4:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 12.6% from its 30-day high with no news headlines or SEC filings providing fundamental context for the drop, suggesting it may be macro- or sector-driven rather than company-specific deterioration. However, the options flow shows highly unusual put volume (z=3.41) on the most recent trading day with a near-parity P/C ratio of 0.92, signaling elevated hedging or directional bearishness — a meaningful risk discount. Health care sector context is mixed (rank 4/11, slightly underperforming SPY on 30d), and earnings are 65 days out, making that a non-factor. With no insider buying to confirm the dip, no catalyst identified, and the macro backdrop of elevated 10Y yields (4.65%) and rising inflation expectations (T5YIFR at 1.8σ above trend), the setup lacks the asymmetric large-rebound characteristics required for a high-conviction buy.

89. ❖Sep 1, 10:22 AMnewsvia finnhub

    3 Healthcare Stocks We Keep Off Our Radar

    Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 22.1% over the past six months while the S&P 500 was up 12.1%.

90. ?Sep 1, 9:50 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is up 1.65% intraday, a modest but real move suggesting some directional conviction. No headlines are present to explain the move, which is common — this could be sector rotation, technical breakout above a key level, or quiet institutional accumulation. The macro context (2Y yields at 4.34, 2.0σ above trend) is mildly headwind for healthcare/medtech names like BAX insofar as higher rates compress valuations, but BAX is not a high-duration growth name — it's a mature medical products company where rate sensitivity is secondary. The rate environment does not strongly argue for a fade here. With 355 minutes remaining (nearly full session left), there is ample time for the move to extend or consolidate, so time decay is not a concern. The move magnitude (1.65%) is below the 2-5% threshold that would signal strong conviction, so this is an ordinary momentum read rather than a high-conviction setup. No reversal signals are evident from the data provided. On balance, the path of least resistance is modest continuation into the close, warranting a probability just above the 0.5 threshold.

91. ❖Aug 30, 10:30 AMnewsvia finnhub

    Everything I Learned from My Hot Chart Summer, and How My 21 Stocks Picks Have Performed.

    Great stock picks are just the start to building a portfolio that can shelter you through whatever the market brings.

92. ▢Aug 25, 8:00 PMjournal

    Agent 5 — Dip Buyer (Evolving) opened long 1 @ $26.61

93. ▢Aug 25, 8:00 PMjournal

    Agent 5 — Dip Buyer (Evolving) opened long 1 @ $26.61

94. ❖Aug 24, 7:11 PMnewsvia finnhub

    The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

    Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.

95. ❖Aug 7, 11:14 AMnewsvia finnhub

    Does Cardinal Health’s New CAO and Recalls Reveal Shifts in Its Risk Profile and Earnings Quality (CAH)?

    In early August 2026, Cardinal Health announced that Anita Zielinski will become Chief Accounting Officer in November, following her interim CFO and senior accounting roles at Baxter and long tenure at Sysco and Ernst & Young, while the company also faced ongoing Class II recalls of subpotent levothyroxine tablets distributed nationwide in the US. This combination of leadership change in Cardinal Health’s finance function and routine but nationwide product recalls comes as analysts are...

96. ❖Aug 4, 1:41 PMnewsvia finnhub

    Baxter International Says Anita Zielinski To Resign As Interim CFO, Effective September 15, 2026

    -SEC Filing

97. ❖Aug 4, 9:25 AMnewsvia finnhub

    Baxter International (BAX) Price Target Increased by 25.96% to 27.05

98. ❖Aug 4, 8:30 AMnewsvia finnhub

    Baxter Announces Cash Tender Offers

    DEERFIELD, Ill., August 04, 2026--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has commenced cash tender offers (each, an "Offer" and collectively, the "Offers") for the maximum principal amount of validly tendered (and not validly withdrawn) notes set forth below (collectively, the "Notes"), such that the aggregate purchase price, not including accrued and unpaid interest, payable in respect of such Notes will not exceed $500 million.

99. ❖Aug 3, 3:05 PMnewsvia finnhub

    Exploring the top movers within the S&P500 index during today's session.

    Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session.

100. ❖Aug 3, 12:35 PMnewsvia finnhub

     Explore the top gainers and losers within the S&P500 index in today's session.

     Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.

101. ❖Aug 2, 11:06 PMnewsvia finnhub

     Baxter International: The Gains Can Continue, But Should Slow

     Baxter International has shown early signs of a turnaround, with improving execution and raised revenue guidance supporting cautious optimism. Learn more about BAX stock here.

102. ❖Aug 1, 9:10 PMnewsvia finnhub

     Baxter (BAX) Stock Gets Fair Value Boost After Q2 Beat And Higher Targets

     Baxter International is back in focus after the fair value estimate in one widely used model moved from US$21.54 to US$27.29, a change of about 27% that feeds directly into updated price target discussions. Analysts are linking this shift to fresh views on earnings execution, segment performance and medium term growth visibility after the latest Q2 results and guidance. As you read on, you will see how to track these changing views and what to watch as the Baxter International story develops...

103. ❖Aug 1, 5:09 PMnewsvia finnhub

     Baxter International (BAX) Is Up 16.8% After Raising 2026 Sales Outlook And Earnings Guidance

     Baxter International Inc. recently reported past Q2 2026 results, with sales rising to US$2,960 million and quarterly net income increasing to US$126 million compared with the prior year. Alongside this, Baxter raised its 2026 sales growth and adjusted earnings guidance while maintaining a quarterly dividend, signaling management’s confidence in its operating direction. Next, we’ll examine how Baxter’s upgraded 2026 guidance, particularly its higher sales outlook, shapes the company’s...

104. ❖Aug 1, 12:02 AMnewsvia finnhub

     Baxter International Q2 Earnings Call Highlights

     Baxter International (NYSE:BAX) reported second-quarter 2026 results that exceeded its expectations, supported by broad-based sales growth, strong demand in Advanced Surgery and drug compounding, and a $75 million tariff refund. The company raised its full-year organic sales-growth outlook and incre

105. ❖Jul 31, 8:23 PMnewsvia finnhub

     Why Baxter International Stock Skyrocketed by 19% This Week

     The company's second-quarter performance was impressive.

106. ❖Jul 31, 5:10 PMnewsvia finnhub

     S&P 500 ends with its first July decline since 2014. Here are the stocks that led the selloff.

     After a whipsaw end to the month, the stock market’s decline was highlighted by the worst month for chip stocks in 24 years.

107. ❖Jul 31, 4:36 PMnewsvia finnhub

     Citigroup Upgrades Baxter International (BAX)

108. ❖Jul 31, 8:12 AMnewsvia finnhub

     TD Cowen Maintains Hold on Baxter International, Raises Price Target to $29

     TD Cowen analyst Joshua Jennings maintains Baxter International (NYSE:BAX) with a Hold and raises the price target from $24 to $29.

109. ❖Jul 31, 7:23 AMnewsvia finnhub

     Do Wall Street Analysts Like Baxter International Stock?

     Baxter International has significantly underperformed the broader market over the past year, although analysts remain neutral amid improving fundamentals and recovery prospects.

110. ❖Jul 31, 6:35 AMnewsvia finnhub

     Wells Fargo Maintains Equal-Weight on Baxter International, Raises Price Target to $23

     Wells Fargo analyst Larry Biegelsen maintains Baxter International (NYSE:BAX) with a Equal-Weight and raises the price target from $19 to $23.

111. ❖Jul 31, 5:41 AMnewsvia finnhub

     Stifel Maintains Hold on Baxter International, Raises Price Target to $28

     Stifel analyst Rick Wise maintains Baxter International (NYSE:BAX) with a Hold and raises the price target from $24 to $28.

112. ❖Jul 31, 4:36 AMnewsvia finnhub

     Citigroup Upgrades Baxter International to Neutral, Raises Price Target to $28

     Citigroup analyst Joanne Wuensch upgrades Baxter International (NYSE:BAX) from Sell to Neutral and raises the price target from $17 to $28.

113. ❖Jul 30, 7:09 PMnewsvia finnhub

     Why Are Baxter (BAX) Shares Soaring Today

     Shares of healthcare company Baxter International (NYSE:BAX) jumped 8.7% in the afternoon session after the company reported second-quarter results that beat analyst expectations on the top and bottom lines and raised its full-year financial forecast.

114. ❖Jul 30, 5:06 PMnewsvia finnhub

     Baxter International Inc (BAX) (Q2 2026) Earnings Call Highlights: Strong Revenue Beat Offsets ...

     Baxter International Inc (BAX) delivered a 5% organic revenue beat in Q2 2026, driven by broad-based growth, but adjusted EPS fell 5% year-over-year due to cost headwinds.

115. ❖Jul 30, 1:05 PMnewsvia finnhub

     In today's session, there are S&P500 stocks with remarkable trading volume.

     Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.

116. ❖Jul 30, 12:02 PMnewsvia finnhub

     BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contract

     Baxter beats second-quarter earnings and revenue estimates, posts broad-based segment growth and raises its 2026 outlook despite margin pressure.

117. ❖Jul 30, 11:33 AMnewsvia finnhub

     Baxter’s shares soar by 17% after reporting positive Q2

     Baxter’s profits rose 5% in Q2 versus the same period in 2025 that was impacted by factors including hurricane damage to a key facility in North Carolina.

118. ❖Jul 30, 10:35 AMnewsvia finnhub

     These S&P500 stocks are gapping in today's session

     Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Thursday. Discover the gap up and gap down stocks in the S&P500 index.

119. ❖Jul 30, 10:00 AMnewsvia finnhub

     Baxter (BAX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

     The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

120. ❖Jul 30, 9:27 AMnewsvia finnhub

     Baxter (NYSE:BAX) Reports Upbeat Q2 CY2026, Stock Jumps 16.1%

     Healthcare company Baxter International (NYSE:BAX) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.3% year on year to $2.96 billion. Its non-GAAP profit of $0.56 per share was 52.5% above analysts’ consensus estimates.

121. ❖Jul 30, 8:35 AMnewsvia finnhub

     Baxter International (BAX) Surpasses Q2 Earnings and Revenue Estimates

     Baxter (BAX) delivered earnings and revenue surprises of +55.56% and +5.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

122. ❖Jul 30, 8:35 AMnewsvia finnhub

     Top S&P500 movers in Thursday's pre-market session

     Pre-market stock analysis of S&P500 stocks on 2026-07-30: top gainers and losers in today's session.

123. ❖Jul 30, 8:24 AMnewsvia finnhub

     Baxter International (NYSE:BAX) Jumps After Q2 Earnings Beat and Raised Outlook

     Baxter International (BAX) crushed Q2 estimates, boosting revenue to $2.96B and EPS to $0.56, while raising full-year guidance, sending shares up 14%.

124. ❖Jul 30, 8:23 AMnewsvia finnhub

     Baxter International Inc. (BAX) Q2 2026 Earnings Call Transcript

     Baxter International Inc. (BAX) Q2 2026 Earnings Call July 30, 2026 8:30 AM EDTCompany ParticipantsKevin Moran - Vice President & Head of Investor...

125. ❖Jul 30, 7:33 AMnewsvia finnhub

     Baxter Jumps After Q2 Beat, Boosted 2026 Guidance Reflects Turnaround Progress

     Baxter stock climbs after second-quarter earnings and revenue topped estimates as the company raised fiscal 2026 sales and profit guidance.

126. ❖Jul 30, 7:15 AMnewsvia finnhub

     Baxter Reports Second-Quarter 2026 Results

     DEERFIELD, Ill., July 30, 2026--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2026.

127. ❖Jul 30, 5:03 AMnewsvia finnhub

     Baxter International Inc. 2026 Q2 - Results - Earnings Call Presentation

     2026-07-30. The following slide deck was published by Baxter International Inc.

128. ❖Jul 30, 3:45 AMnewsvia finnhub

     Stocks making the biggest moves premarket: Meta, Microsoft, Teladoc, Norwegian Cruise Line & more

     These are the stocks posting the largest moves in the premarket.

129. ❖Jul 30, 3:16 AMnewsvia finnhub

     Baxter International Raises FY2026 Adj EPS Guidance from $1.85-$2.05 to $1.95-$2.15 vs $1.91 Est; Raises FY2026 Sales Guidance from $11.244B-$11.356B to $11.581B-$11.694B vs $11.357B Est

     Baxter International (NYSE:BAX) raises FY2026 Adj EPS guidance from $1.85-$2.05 to $1.95-$2.15 vs $1.91 analyst estimate. Raises FY2026 sales outlook from $11.244 billion-$11.356 billion to $11.581 billion-$11.694

130. ❖Jul 30, 3:15 AMnewsvia finnhub

     Baxter Intl Q2 Adj. EPS $0.54 Beats $0.37 Estimate, Sales $2.960B Beat $2.795B Estimate

     Baxter Intl (NYSE:BAX) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.37 by 45.95 percent. This is a 8.47 percent decrease over earnings of $0.59 per share from the same

131. ▢Jul 29, 8:00 PMjournal

     Agent 4 — Dip Buyer (Frozen) opened long 104 @ $26.77

132. ▢Jul 29, 8:00 PMjournal

     Agent 20 — SIR Price/Volume opened long 66 @ $26.77

133. ❖Jul 29, 12:05 PMnewsvia finnhub

     Baxter Earnings: What To Look For From BAX

     Healthcare company Baxter International (NYSE:BAX) will be reporting results this Thursday before market open. Here’s what you need to know.

134. ❖Jul 29, 10:54 AMnewsvia finnhub

     Watch These 4 Medical Product Stocks for Q2 Earnings: Beat or Miss?

     Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.

135. ❖Jul 29, 8:09 AMnewsvia finnhub

     Baxter (BAX) Stock May Be 19% Undervalued On Cash Flow

     Baxter International stock has delivered a steep decline of about 64.6% over the past five years, yet current valuation checks suggest the shares may now be trading below an estimate of intrinsic value. With both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples screening the stock as undervalued, investors are weighing whether this signals an opportunity or a value trap. Baxter International is down roughly 64.6% over five years, which puts recent share price...

136. ▣Jul 28, 8:00 PMjournaltarget

     Agent 20 — SIR Price/Volume closed long 86 @ $24.76 (+$382.70)

     Target hit: close $24.76 ≥ target $24.37

137. ❖Jul 28, 11:14 AMnewsvia finnhub

     UBS Maintains Neutral on Baxter International, Raises Price Target to $25

     UBS analyst Patrick Wood maintains Baxter International (NYSE:BAX) with a Neutral and raises the price target from $19 to $25.

138. ❖Jul 28, 6:42 AMnewsvia finnhub

     Stifel Maintains Hold on Baxter International, Raises Price Target to $24

     Stifel analyst Rick Wise maintains Baxter International (NYSE:BAX) with a Hold and raises the price target from $19 to $24.

139. ❖Jul 28, 12:13 AMnewsvia finnhub

     Why Baxter (BAX) Stock Is Up Today

     Shares of healthcare company Baxter International (NYSE:BAX) jumped 3.6% in the afternoon session after TD Cowen raised its price target on the stock to $24 from $20. The firm maintained its hold rating on the shares, which suggests the analyst recommends neither buying nor selling the stock at its current price. However, the increased price target indicates a more positive valuation outlook for the company than before. The move from the investment firm comes as Baxter holds an average rating of

140. ▢Jul 27, 8:00 PMjournal

     Agent 7 — Day Trader opened long 119 @ $24.42

141. ▣Jul 27, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 119 @ $24.33 (-$11.31)

     EOD forced close — day trader never carries overnight

142. ▢Jul 1, 8:00 PMjournal

     Agent 7 — Day Trader opened long 132 @ $22.49

143. ▣Jul 1, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 132 @ $22.48 (-$1.98)

     EOD forced close — day trader never carries overnight

144. ▣Jun 29, 8:00 PMjournalstop

     options_momentum closed long 400 @ $0.79 (-$77.91)

     Stop: premium $0.79 ≤ trailing floor $0.87 (peak $1.16 × 0.75)

145. ▢Jun 24, 8:00 PMjournal

     options_momentum opened long 400 @ $0.98

146. ▣Jun 16, 8:00 PMjournalstop

     options_momentum closed long 500 @ $1.01 (+$64.66)

     Stop: premium $1.01 ≤ trailing floor $1.01 (peak $1.35 × 0.75)

147. ▢Jun 10, 8:00 PMjournal

     Agent 20 — SIR Price/Volume opened long 86 @ $20.31

148. ▢Jun 8, 8:00 PMjournal

     options_momentum opened long 500 @ $0.88

149. ▣May 28, 8:00 PMjournalstop

     options_momentum closed long 900 @ $0.76 (-$141.36)

     Stop: premium $0.76 ≤ trailing floor $0.85 (peak $1.14 × 0.75)

150. ▢May 19, 8:00 PMjournal

     options_momentum opened long 900 @ $0.92